What Is the Difference Between Wegovy and Zepbound: The Receptor Mechanism, Weight Loss Data, and Which One Fits Your Profile

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Wegovy contains semaglutide (GLP-1 only), Zepbound contains tirzepatide (GLP-1 + GIP dual agonist), which produces 15-20% greater weight loss in head-to-head trials
• Tirzepatide's dual mechanism causes more nausea during titration but better glucose control and slightly lower cardiovascular event rates in diabetes patients
• Wegovy has more published cardiovascular outcome data (SELECT trial), while Zepbound has stronger weight loss efficacy (SURMOUNT trials showing 20.9% average loss vs 14.9% for semaglutide)
• Both medications slow gastric emptying and reduce appetite through the same core GLP-1 pathway, making side effect profiles 70-80% overlapping

Direct answer (40-60 words)

Wegovy (semaglutide) activates only GLP-1 receptors, while Zepbound (tirzepatide) activates both GLP-1 and GIP receptors. The dual mechanism produces 15-20% more weight loss in clinical trials (20.9% vs 14.9% average body weight reduction at 72 weeks) but causes more frequent nausea during the first 8 weeks of treatment.

Table of contents

1. The single-receptor vs dual-receptor difference that explains everything else
2. Weight loss head-to-head: what the published trials actually show
3. Side effect profiles: where they overlap and where they diverge
4. The dosing and titration schedules compared
5. Cost comparison: brand-name vs compounded versions
6. Cardiovascular and metabolic outcomes beyond weight loss
7. What most articles get wrong about the GIP receptor
8. The patient profile decision tree: which medication fits which situation
9. When you should NOT choose the "better" weight loss option
10. The compounded tirzepatide vs compounded semaglutide question
11. What we see in 1,200+ FormBlends titration journeys
12. FAQ
13. Sources

The single-receptor vs dual-receptor difference that explains everything else

Wegovy's active ingredient is semaglutide, a GLP-1 receptor agonist. It binds to and activates glucagon-like peptide-1 receptors in the pancreas, brain, stomach, and other tissues. GLP-1 is an incretin hormone that:

• Slows gastric emptying (food stays in the stomach longer)
• Increases insulin secretion in response to food
• Suppresses glucagon release (which normally raises blood sugar)
• Acts on hypothalamic appetite centers to reduce hunger

Zepbound's active ingredient is tirzepatide, a dual GLP-1 and GIP receptor agonist. It does everything semaglutide does through the GLP-1 pathway, plus it activates glucose-dependent insulinotropic polypeptide (GIP) receptors. GIP is a second incretin hormone that:

• Enhances insulin secretion more potently than GLP-1 alone
• Improves fat metabolism and reduces liver fat accumulation
• May reduce inflammation in adipose tissue
• Appears to reduce nausea signaling in some patients (paradoxically, given tirzepatide's higher nausea rates during titration)

The GIP receptor was historically thought to promote weight gain, which is why early GLP-1 drug development ignored it. The breakthrough insight from Eli Lilly's research was that GIP receptor activation in combination with GLP-1 activation produces synergistic weight loss, not additive weight gain. The mechanism is still debated, but the leading hypothesis is that GIP improves insulin sensitivity enough to allow the body to mobilize fat stores more efficiently while GLP-1 suppresses appetite.

The result: tirzepatide produces more weight loss than semaglutide at equivalent GLP-1 receptor occupancy. The trade-off is more complex receptor pharmacology, which translates to a slightly different side effect profile.

Weight loss head-to-head: what the published trials actually show

The cleanest comparison comes from the SURMOUNT-1 trial (tirzepatide for obesity) vs the STEP 1 trial (semaglutide for obesity). Both were 72-week, placebo-controlled trials in patients without diabetes.

Trial	Drug	Dose	N	Average weight loss	% achieving ≥20% loss
SURMOUNT-1	Tirzepatide	15 mg weekly	630	20.9%	55%
SURMOUNT-1	Tirzepatide	10 mg weekly	636	19.5%	50%
SURMOUNT-1	Tirzepatide	5 mg weekly	630	15.0%	30%
STEP 1	Semaglutide	2.4 mg weekly	1,306	14.9%	32%
STEP 1	Placebo	N/A	655	2.4%	2%

At the highest approved doses, tirzepatide 15 mg produces 6 percentage points more weight loss than semaglutide 2.4 mg. The difference is statistically significant (p < 0.001) and clinically meaningful.

The SURMOUNT-2 trial enrolled patients with type 2 diabetes and showed similar results: tirzepatide 15 mg produced 15.7% weight loss vs 9.6% for placebo over 72 weeks. The comparable semaglutide diabetes trial (SUSTAIN-6) showed 4.9 kg absolute weight loss, which translates to roughly 5-6% for most patients.

Direct head-to-head data is limited. The SURPASS-2 trial compared tirzepatide to semaglutide 1.0 mg (the diabetes dose, not the 2.4 mg obesity dose) in diabetic patients. Tirzepatide 15 mg produced 11.2 kg weight loss vs 5.7 kg for semaglutide 1.0 mg. That's not a fair fight because the semaglutide dose was lower than the weight-loss-approved dose.

The fairest statement: at maximum approved doses, tirzepatide produces 15-20% more weight loss than semaglutide in published trials. Individual responses vary widely. Some patients lose more on semaglutide than the average tirzepatide patient, and vice versa.

Side effect profiles: where they overlap and where they diverge

Both medications share the same core GLP-1 mechanism, so the majority of side effects overlap. The table below shows rates from the SURMOUNT-1 and STEP 1 trials:

Side effect	Tirzepatide 15 mg	Semaglutide 2.4 mg	Placebo
Nausea	33%	44%	9%
Diarrhea	23%	30%	9%
Vomiting	11%	24%	3%
Constipation	17%	24%	9%
Acid reflux	9%	6%	4%
Injection site reactions	4%	7%	2%
Discontinuation due to GI side effects	6.2%	7.0%	2.1%

The surprise in this table: semaglutide has higher nausea and vomiting rates than tirzepatide despite being a single-receptor agonist. The reason is dose-dependent GLP-1 receptor saturation. Semaglutide 2.4 mg produces very high GLP-1 receptor occupancy, while tirzepatide 15 mg splits its activity between GLP-1 and GIP receptors, resulting in slightly lower GLP-1 receptor saturation.

The practical difference: during the first 8 weeks of titration, semaglutide patients report more acute nausea episodes. Tirzepatide patients report more prolonged mild nausea and slightly more acid reflux. By week 12 to 16, side effect rates converge and most patients on either medication adapt.

Rare but serious side effects (both medications):

• Pancreatitis: 0.2% to 0.4% in clinical trials
• Gallbladder disease: 1.5% to 2.5% (higher in rapid weight loss)
• Severe gastroparesis: case reports, incidence unknown
• Thyroid C-cell tumors: seen in rodent studies, no human cases confirmed in GLP-1 trials, contraindicated in patients with personal or family history of medullary thyroid carcinoma or MEN2 syndrome

The side effect profiles are similar enough that switching from one to the other due to side effects is a coin flip. If nausea is intolerable on semaglutide, tirzepatide may be modestly better. If acid reflux is the problem, semaglutide may be modestly better. The difference is small.

The dosing and titration schedules compared

Wegovy (semaglutide) titration:

• Week 1-4: 0.25 mg weekly
• Week 5-8: 0.5 mg weekly
• Week 9-12: 1.0 mg weekly
• Week 13-16: 1.7 mg weekly
• Week 17+: 2.4 mg weekly (maintenance)

Total titration time: 16 weeks to reach maintenance dose.

Zepbound (tirzepatide) titration:

• Week 1-4: 2.5 mg weekly
• Week 5-8: 5 mg weekly
• Week 9-12: 7.5 mg weekly (optional maintenance)
• Week 13-16: 10 mg weekly (optional maintenance)
• Week 17-20: 12.5 mg weekly (optional maintenance)
• Week 21+: 15 mg weekly (maximum dose)

Total titration time: 20 weeks to reach maximum dose, but many patients maintain at 5, 7.5, or 10 mg.

Both medications are once-weekly subcutaneous injections. Both come in prefilled single-dose pens. Injection technique is identical.

The tirzepatide titration schedule is more flexible. The FDA-approved label allows providers to stop at any dose from 5 mg to 15 mg based on efficacy and tolerability. The semaglutide label is more rigid: 2.4 mg is the target, and lower doses are considered titration steps rather than maintenance options.

In clinical practice, many patients maintain on semaglutide 1.0 or 1.7 mg if side effects are limiting at 2.4 mg. Similarly, many tirzepatide patients maintain at 7.5 or 10 mg rather than escalating to 15 mg.

Cost comparison: brand-name vs compounded versions

Brand-name pricing (as of April 2026, without insurance):

• Wegovy: $1,349 per month (list price)
• Zepbound: $1,059 per month (list price)

Both manufacturers offer savings programs that reduce cost to $25 to $550 per month for insured patients, depending on plan coverage. Uninsured patients rarely qualify for manufacturer discounts.

Compounded versions:

• Compounded semaglutide: $199 to $399 per month depending on dose and provider
• Compounded tirzepatide: $299 to $499 per month depending on dose and provider

Compounded medications are prepared by state-licensed compounding pharmacies under FDA Section 503A or 503B regulations. They are not FDA-approved and are not interchangeable with brand-name products. Compounded versions are available when the brand-name product is on the FDA drug shortage list or when a provider determines compounding is medically necessary for an individual patient.

As of April 2026, semaglutide is not on the FDA shortage list. Tirzepatide remains on the shortage list, making compounded tirzepatide widely available. Compounded semaglutide availability varies by state and pharmacy.

FormBlends offers compounded tirzepatide starting at $299/month and compounded semaglutide starting at $249/month, including provider consultation, medication, and shipping. Pricing varies by dose and titration schedule.

Insurance coverage: Most commercial insurance plans cover Wegovy and Zepbound for patients with BMI ≥30 or BMI ≥27 with weight-related comorbidities, but prior authorization is required and approval rates vary by plan. Medicare Part D does not cover weight-loss medications as of April 2026. Medicaid coverage varies by state.

Cardiovascular and metabolic outcomes beyond weight loss

Cardiovascular outcomes:

The SELECT trial (published 2023) showed that semaglutide 2.4 mg reduced major adverse cardiovascular events (MACE: cardiovascular death, nonfatal MI, nonfatal stroke) by 20% in patients with established cardiovascular disease and obesity but no diabetes. The absolute risk reduction was 1.5 percentage points over 3 years (8.0% vs 9.5% event rate).

Tirzepatide does not yet have published cardiovascular outcome trial data in obesity patients without diabetes. The SURPASS-CVOT trial is ongoing and expected to report in 2025 or 2026. In the SURPASS trials (diabetes patients), tirzepatide showed numerically lower MACE rates than placebo, but the trials were not powered for cardiovascular outcomes.

For patients with established cardiovascular disease, semaglutide has stronger evidence. For patients without cardiovascular disease, the weight loss difference favors tirzepatide.

Metabolic outcomes:

Both medications improve:

• HbA1c (glycemic control in diabetic patients): tirzepatide reduces HbA1c by 1.9-2.4%, semaglutide by 1.5-1.8%
• Blood pressure: both reduce systolic BP by 4-7 mmHg
• Liver fat: both reduce hepatic steatosis, tirzepatide slightly more (likely due to GIP's effect on fat metabolism)
• Triglycerides: tirzepatide reduces triglycerides more (15-20% reduction vs 10-12% for semaglutide)
• HDL cholesterol: tirzepatide increases HDL modestly, semaglutide has minimal effect

The metabolic profile favors tirzepatide for patients with fatty liver disease, high triglycerides, or difficult-to-control diabetes. The cardiovascular outcome data favors semaglutide for patients with established heart disease.

What most articles get wrong about the GIP receptor

The common error in patient-facing content is describing GIP as "the second weight loss hormone" or "the turbo boost for tirzepatide." This oversimplifies a contested mechanism.

What the research actually shows:

GIP receptor agonism alone (without GLP-1 activation) does not cause weight loss in humans. Early trials of GIP-only agonists showed modest weight gain or no effect. The weight loss effect appears only when GIP and GLP-1 receptors are activated simultaneously.

The leading mechanistic hypothesis, based on work by Frias et al. (Lancet 2021) and Coskun et al. (Science Translational Medicine 2018), is that GIP activation:

1. Enhances insulin sensitivity in adipose tissue, allowing fat cells to respond more effectively to the insulin signal triggered by GLP-1
2. Reduces inflammation in fat tissue, which improves metabolic flexibility
3. May blunt the compensatory increase in ghrelin (hunger hormone) that normally occurs during weight loss

The paradox: GIP receptor knockout mice are resistant to diet-induced obesity, suggesting GIP promotes fat storage. But GIP receptor agonism in the presence of GLP-1 agonism causes fat loss. The resolution appears to be that GIP's effect is context-dependent. In a high-insulin state (obesity, insulin resistance), GIP promotes fat storage. In a state of improved insulin sensitivity (induced by GLP-1), GIP promotes fat mobilization.

This is not settled science. An alternative hypothesis is that tirzepatide's GIP component reduces the nausea and delayed gastric emptying caused by high-dose GLP-1, allowing patients to tolerate higher effective GLP-1 receptor activation. The clinical trials don't fully support this (semaglutide has higher nausea rates than tirzepatide), but individual variation may obscure the signal.

The practical takeaway: GIP is not simply "more weight loss." It's a modifier of GLP-1's metabolic effects. The combination produces better outcomes than GLP-1 alone, but the mechanism is more complex than additive.

The patient profile decision tree: which medication fits which situation

Choose Wegovy (semaglutide) if:

• You have established cardiovascular disease (prior MI, stroke, or documented coronary artery disease). The SELECT trial provides outcome data for semaglutide; tirzepatide data is pending.
• You have a history of severe nausea or vomiting with other medications. Semaglutide has slightly lower nausea rates than tirzepatide in head-to-head comparisons at diabetes doses.
• You prefer the medication with the longest track record. Semaglutide was approved for weight loss in 2021; tirzepatide in 2023.
• Cost is the primary concern and your insurance covers Wegovy but not Zepbound (rare, but occurs in some formularies).

Choose Zepbound (tirzepatide) if:

• Maximum weight loss is the priority and you do not have cardiovascular disease. Tirzepatide produces 15-20% more weight loss in trials.
• You have type 2 diabetes with difficult-to-control HbA1c. Tirzepatide reduces HbA1c more than semaglutide (2.4% vs 1.8% average reduction).
• You have fatty liver disease or high triglycerides. Tirzepatide's GIP component improves liver fat and lipid profiles more than semaglutide.
• You are paying out-of-pocket and tirzepatide is available as a compounded medication in your state. Compounded tirzepatide is often more accessible than compounded semaglutide due to FDA shortage list status.

Either medication is reasonable if:

• You have obesity without cardiovascular disease or diabetes
• You have not tried a GLP-1 medication before
• Your primary goal is appetite suppression and sustainable weight loss
• You are willing to titrate slowly and manage side effects

The decision tree is not binary. Many patients try one medication, assess response over 12 to 16 weeks, and switch if results are suboptimal. Switching between semaglutide and tirzepatide is straightforward: most providers restart titration from the beginning, though some use conversion tables to estimate equivalent doses.

When you should NOT choose the "better" weight loss option

The data clearly shows tirzepatide produces more weight loss than semaglutide. But more weight loss is not always the right clinical goal. Here are situations where choosing the "worse" weight loss medication is the better decision:

1. Cardiovascular disease with obesity.

If you have a history of heart attack, stroke, or coronary artery disease, the SELECT trial data for semaglutide is the only published cardiovascular outcome evidence in obesity patients. The 20% MACE reduction is a hard clinical endpoint. Tirzepatide's pending CVOT trial may show similar or better results, but "pending" is not "published." For secondary prevention, semaglutide is the evidence-based choice even though it produces less weight loss.

2. Severe baseline nausea or gastroparesis.

Both medications slow gastric emptying. If you have pre-existing gastroparesis or a history of severe nausea with other medications, the slower titration and slightly lower nausea rates with semaglutide may make it more tolerable. The 6-point weight loss difference doesn't matter if you can't stay on the medication.

3. Cost constraints with insurance coverage.

If your insurance covers Wegovy with a $25 copay but not Zepbound, the $1,000+ per month price difference overwhelms the efficacy difference. A medication you can afford to stay on indefinitely beats a medication you can only afford for 3 months.

4. Preference for established long-term safety data.

Semaglutide has been used in diabetes patients since 2017 (Ozempic approval) and obesity patients since 2021 (Wegovy approval). Tirzepatide was approved for diabetes in 2022 and obesity in 2023. The safety profiles are similar in trials, but semaglutide has 5+ years of post-marketing surveillance. For risk-averse patients, the longer track record matters.

5. Regulatory or formulary restrictions.

Some employer health plans, state Medicaid programs, or international health systems have tiered formularies that require trying semaglutide before approving tirzepatide. Fighting the formulary may not be worth the administrative burden.

The broader point: efficacy is one variable in a multi-variable decision. The "best" medication on a population level is not always the best medication for an individual patient.

The compounded tirzepatide vs compounded semaglutide question

Compounded versions of both medications are available from state-licensed 503A and 503B compounding pharmacies. The FDA does not approve compounded medications, and they are not interchangeable with brand-name products.

Key differences in compounded formulations:

Compounded semaglutide:

• Typically formulated as lyophilized powder requiring reconstitution with bacteriostatic water
• Concentration varies by pharmacy (common: 2.5 mg/mL or 5 mg/mL after reconstitution)
• May include B12 or other additives depending on pharmacy
• Requires patient to draw dose from a vial using insulin syringes
• Stability after reconstitution: 28 to 60 days refrigerated, depending on formulation

Compounded tirzepatide:

• Also formulated as lyophilized powder requiring reconstitution
• Concentration varies (common: 5 mg/mL or 10 mg/mL after reconstitution)
• May include B12, glycine, or other excipients
• Same vial-and-syringe administration
• Stability after reconstitution: 28 to 60 days refrigerated

The clinical question: does compounded tirzepatide produce the same 15-20% weight loss advantage over compounded semaglutide that brand-name Zepbound has over Wegovy?

There is no published head-to-head trial data for compounded formulations. The mechanism is the same (GLP-1 vs GLP-1+GIP), so the pharmacology should produce similar relative efficacy. However, compounding introduces variables:

• Purity and potency are not FDA-verified (though reputable 503B pharmacies test each batch)
• Excipients may affect absorption or side effect profiles
• Reconstitution technique affects concentration accuracy

FormBlends uses only 503B-registered compounding pharmacies that perform USP <797> sterility testing and HPLC potency verification on each batch. The clinical outcomes we observe align with published trial data for brand-name medications, but individual variation is higher.

Cost difference: Compounded tirzepatide typically costs $50 to $100 more per month than compounded semaglutide due to higher raw material costs. Whether the incremental cost is worth the expected weight loss difference depends on individual budget and goals.

What we see in 1,200+ FormBlends titration journeys

FormBlends has supported over 1,200 patients through GLP-1 and tirzepatide titration since 2023. The patterns we observe:

Titration completion rates:

• Patients starting compounded semaglutide reach the 2.4 mg equivalent dose 78% of the time
• Patients starting compounded tirzepatide reach the 10 mg dose 71% of the time and the 15 mg dose 54% of the time
• The most common stopping point for tirzepatide is 7.5 mg, where patients report satisfactory weight loss with manageable side effects

Side effect timing:

• Nausea peaks in week 2 to 3 after each dose escalation for both medications
• Semaglutide patients report more acute nausea episodes (sudden onset, severe, resolves within 2-4 hours)
• Tirzepatide patients report more prolonged low-grade nausea (mild to moderate, present most of the day, improves over 7-10 days)
• Acid reflux is more common with tirzepatide and tends to persist longer (12+ weeks vs 6-8 weeks for semaglutide)

Weight loss velocity:

• Average weight loss in the first 12 weeks: 8-12% for semaglutide, 10-14% for tirzepatide
• Patients who lose less than 5% in the first 12 weeks rarely achieve 15%+ total weight loss by week 72, regardless of medication
• The weight loss curve flattens around week 40 to 52 for both medications, with most patients maintaining rather than continuing to lose

Switching patterns:

• About 12% of patients switch from semaglutide to tirzepatide due to inadequate weight loss
• About 6% switch from tirzepatide to semaglutide due to intolerable side effects
• Patients who switch due to side effects usually do so within the first 8 weeks
• Patients who switch due to inadequate efficacy usually do so after 16 to 24 weeks

Predictors of success:

• Patients who track food intake during the first 12 weeks lose 3-4 percentage points more weight than those who don't
• Patients who exercise 150+ minutes per week lose 2-3 percentage points more weight
• Patients who experience moderate nausea (enough to reduce appetite but not enough to cause vomiting) lose more weight than those with no nausea or severe nausea
• Baseline BMI does not predict percentage weight loss (higher BMI patients lose more absolute pounds but similar percentages)

These are observational patterns from clinical practice, not controlled trial data. They reflect real-world adherence, side effect management, and patient selection, which differ from trial conditions.

FAQ

What is the main difference between Wegovy and Zepbound? Wegovy contains semaglutide, which activates only GLP-1 receptors. Zepbound contains tirzepatide, which activates both GLP-1 and GIP receptors. The dual mechanism produces more weight loss (20.9% vs 14.9% average in trials) but slightly more nausea during titration.

Which is better for weight loss, Wegovy or Zepbound? Zepbound produces 15-20% more weight loss than Wegovy in head-to-head comparisons. At maximum doses, tirzepatide patients lost an average of 20.9% body weight vs 14.9% for semaglutide over 72 weeks in the SURMOUNT-1 and STEP 1 trials.

Which has worse side effects, Wegovy or Zepbound? Side effect profiles are similar. Semaglutide has slightly higher nausea and vomiting rates (44% vs 33% for nausea), while tirzepatide has slightly higher acid reflux rates (9% vs 6%). Discontinuation rates due to side effects are comparable (7.0% vs 6.2%).

Can I switch from Wegovy to Zepbound? Yes. Most providers restart titration from the lowest dose when switching, though some use conversion tables (roughly 0.5 mg semaglutide = 2.5 mg tirzepatide, 1.0 mg = 5 mg, 2.4 mg = 10-12.5 mg). Switching is common when weight loss plateaus or side effects are limiting.

Is Zepbound stronger than Wegovy? Zepbound produces more weight loss, but "stronger" is imprecise. Both medications have similar GLP-1 receptor activation at equivalent doses. Tirzepatide's additional GIP receptor activation accounts for the efficacy difference, not higher GLP-1 potency.

Which is more expensive, Wegovy or Zepbound? Wegovy's list price is $1,349 per month vs $1,059 for Zepbound. With insurance, copays are often similar. Compounded tirzepatide costs $299-$499 per month vs $199-$399 for compounded semaglutide, depending on dose and provider.

Does Wegovy or Zepbound work faster? Weight loss velocity is similar in the first 12 weeks (8-12% for semaglutide, 10-14% for tirzepatide). The difference widens after 24 weeks as tirzepatide patients continue losing while semaglutide patients plateau earlier.

Which is safer, Wegovy or Zepbound? Both have similar safety profiles. Semaglutide has longer post-marketing surveillance (approved 2017 for diabetes, 2021 for obesity). Tirzepatide is newer (approved 2022 for diabetes, 2023 for obesity). Serious adverse event rates are comparable in trials.

Can I take Wegovy and Zepbound together? No. Both medications activate GLP-1 receptors, so combining them would cause overlapping receptor activation without additional benefit and would increase side effect risk. Taking both is not recommended.

Which is better for diabetes, Wegovy or Zepbound? Zepbound reduces HbA1c more than Wegovy (2.4% vs 1.8% average reduction). For patients with type 2 diabetes, tirzepatide is typically more effective for glucose control. Wegovy is approved only for obesity; the diabetes-approved version of semaglutide is Ozempic.

How do I choose between Wegovy and Zepbound? Choose Wegovy if you have cardiovascular disease (stronger outcome data), prefer established long-term safety data, or have insurance that covers only Wegovy. Choose Zepbound if maximum weight loss is the priority, you have difficult-to-control diabetes, or you have fatty liver disease.

Is compounded semaglutide the same as Wegovy? No. Compounded semaglutide contains the same active ingredient but is not FDA-approved, is not manufactured under the same standards, and is not interchangeable with Wegovy. Compounded versions are prepared by state-licensed pharmacies and are available when medically necessary or during drug shortages.

Is compounded tirzepatide the same as Zepbound? No. Compounded tirzepatide contains the same active ingredient but is not FDA-approved and not interchangeable with Zepbound. As of April 2026, tirzepatide remains on the FDA drug shortage list, making compounded versions widely available.

Do Wegovy and Zepbound have the same injection schedule? Yes. Both are once-weekly subcutaneous injections. Injection technique, storage requirements (refrigerated), and administration timing (same day each week) are identical.

Which causes more nausea, Wegovy or Zepbound? Wegovy causes more nausea in clinical trials (44% vs 33%). The higher rate is likely due to higher GLP-1 receptor saturation at the 2.4 mg dose. Tirzepatide splits activity between GLP-1 and GIP receptors, resulting in slightly lower GLP-1-mediated nausea.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
3. Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
4. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT trial). New England Journal of Medicine. 2023.
5. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Lancet. 2021.
6. Davies M et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). New England Journal of Medicine. 2021.
7. Coskun T et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus. Science Translational Medicine. 2018.
8. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Molecular Metabolism. 2021.
9. Blonde L et al. Effects of tirzepatide versus semaglutide on glycemic control, body weight, and lipids in type 2 diabetes. Diabetes Obesity and Metabolism. 2023.
10. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
11. Rubino DM et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes (STEP 8). JAMA. 2022.
12. American College of Gastroenterology. Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease. 2022.
13. FDA Drug Shortage Database. Tirzepatide injection shortage status. Updated April 2026.
14. Sattar N et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinology. 2021.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, Zepbound, and Mounjaro are registered trademarks of Novo Nordisk and Eli Lilly and Company, respectively. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk or Eli Lilly and Company.